RayzeBio’s Post

Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes https://lnkd.in/dGrAbuNG #GuardantINFORM The data support use of a well-validated ctDNA assay to detect MSI-H across solid tumors and suggest prolonged PFS in patients treated with IO-containing regimens after detection. Tumor-agnostic, ctDNA-based MSI testing may be reliable for rapid decision making.

Vivos Inc. (@vivosincusa), a biotech firm developing a pioneering injectable brachytherapy device, has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA). This move brings the company one step closer to initiating human clinical trials for its Radiogel™ Precision Radionuclide Therapy, a groundbreaking approach to treating solid metastatic tumors, particularly in lymph nodes associated with papillary thyroid cancer. RadioGel, an Yttrium-90-based injectable device, is designed for patients ineligible for surgery or those who have chosen not to undergo the procedure. It involves directly injecting a hydrogel containing Yttrium-90 phosphate microparticles into the tumor, allowing for a more localized and potent radiation treatment compared to traditional external-beam therapies. 'We are eager to secure the FDA's IDE approval so that we can submit our plan to the Mayo Clinic's Independent Review Board (IRB) for clearance to initiate the first in human clinical trials,' said Dr. Michael Korenko, President and CEO of Vivos. 'This is an exciting time for Vivos, and we are committed to bringing a new treatment option to patients in the fight against challenging cancer types.' The IDE application marks Vivos' first filing since receiving FDA Breakthrough Device Designation for RadioGel, which aims to accelerate the development and review of innovative treatments. The technology behind RadioGel allows for the safe delivery of higher doses necessary for treating non-resectable and radiation-resistant cancers. #cancertreatment #biotechnology #fda #radiogel #vivosinc @vivosincusa

Surfacing data from the Phase III INDIGO trial of Vorasidenib, an anti-cancer medication generated by Servier Pharmaceuticals, proved tumor reduction in volume for patients with IDH-mutant diffuse glioma, a type of brain tumor. 331 patients participated; 163 placed on placebo and 168 patients given 40 mg of Vorasidenib. Results were measured by a radiology committee which showed high contrast among placebo patients, that experienced tumor growth of about 13.9%, and medication-receiving individuals, that showed tumor shrinkage of 2.5% every 6 months. The INDIGO trial continues to reveal positive results for oncological research, learn more at the link! https://hubs.li/Q029x7V20

More good news for a GSU Licensee!

Research highlights of the past week from studies with participation from the Phase 1 Unit: Results published from #DESTINYPanTumor01 study demostrating efficacy of HER2-targeted antibody-drug-conjugate in HER2 mutated tumors across histologies https://lnkd.in/dSGN4jTQ #HER2 #ADC #precisiononcology Results from the #FIGHT207 phase2 basket trial with data on FGFR inhibition across FGFR1-3 alterations in various tumor types https://lnkd.in/d35mknnM #FGFR Dose optimization of an oral ATR-inhibitor in the #TRESR study https://lnkd.in/dbQxA7Ch #ATR #targetedtherapy

ENHERTU(R) Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Usually if a patient has HNSCC and upto metastatic stage, that is hard enough for oncologist to deal with. Even more desperate if the patient is with PD-L1 level less than 1%, in which case anti-PD1 drugs are not meant to be beneficial. Then if that patient is not suitable to take chemotherapy, practically, out of option so far. However, things are about to change from now on, because of this small peptide, Eftilagimod Alpha, from Immutep!

The 40mg EVANGELINE data is extremely encouraging as it shows that (Z)-endoxifen can not only stop ER breast cancer from growing, but it can also shrink or eliminate the tumor, as measured by MRI imaging. The depth of response at 40mg may even improve in the next phase of the study where we are now treating women with 80mg of (Z)-endoxifen daily. We expect this dose to deliver the optimal steady-state plasma concentrations required to fully target PKCβ1 inhibition and further enhance (Z)-endoxifen’s antitumor efficacy. $ATOS #breasrcancer https://lnkd.in/gXbc2msF